Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Can someone enlight me with transaminase mistery...

<< Previous

Bullboard Posts

Next >>

Comment by woundedkneeon Aug 23, 2021 6:59am

259 Views

Post# 33747339

RE:RE:Can someone enlight me with transaminase mistery...

So to put it in layman's terms, Naproxan is hard on the stomach and causes abnormal liver enzymes in 4 out of 100,000 users. Tylenol, according to google, has so many side effects(including serious liver damage) it's hard to imagine it being on the market as an otc drug. It is always amazes me that there are these double standards. I guess if you have enough warning labels on your product and grease a few pockets that is a prerequisite for HC or FDA approval.

<< Previous

Bullboard Posts

Next >>

Soma Gold poised to extend profitable track record